Alkem Labs Announces Record Date for Interim Dividend
Alkem Laboratories has set February 20, 2026, as the record date for its interim dividend. The dividend will be paid after March 11, 2026. The company also reported its financial results for the nine months ended December 31, 2025, with total income at ₹649.88 crore.
The declaration of an interim dividend is a positive event for shareholders and can be seen as a sign of financial health. However, it does not represent a fundamental change in the business operations or strategy.
The announcement is positive as it declares an interim dividend, which is a direct benefit to shareholders. The company's financial performance also shows growth compared to the previous year.
Alkem Laboratories Limited has announced the record date for determining the entitlement of shareholders to the interim dividend approved by the Board of Directors. The record date has been fixed as Friday, 20th February, 2026.
Shareholders whose names appear in the Register of Members of the Company or as beneficial owners in the depositories, in respect of such of the aforesaid equity shares as are received by the Company in dematerialized form prior to the aforesaid record date, will be entitled to the interim dividend.
The interim dividend will be paid on or after 11th March, 2026. The announcement also includes details about the company's financial results for the quarter and nine months ended December 31, 2025, and December 31, 2024. For the nine months ended December 31, 2025, total income was ₹649.876 crore, compared to ₹358.756 crore for the same period in the previous year. Profit after tax for the nine months was ₹0.428 crore, compared to ₹0.079 crore in the prior year period.
The company has also provided information regarding the disclosure of material/financial results under SEBI regulations and has made the financial results available on its website and the websites of BSE and NSE. Details regarding unclaimed dividends and the process for claiming them are also included.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.